Compassionate use study offers AML patients continued access to experimental oral chemo

This study gives a small group of adults with acute myeloid leukemia (AML) continued access to an oral form of the chemotherapy drug azacitidine after they finished a previous trial. The main goal is to track any side effects and see how safe the drug is over a longer period. About 20 people who already took the drug in an earlier study can join, but it is not a cure—it is meant to help control the disease.